# Biotech Daily

Tuesday August 25, 2026

*Daily news on ASX-listed biotechnology companies*

*** ASX, BIOTECH UP: PARADIGM UP 12.5%; NANOSONICS DOWN 17%**

*** NEUREN: EU APPROVES ACADIA'S DAYBU (TROFINETIDE) FOR RETT SYNDROME**

*** CONTROL BIONICS WINS UK NEUROSTRIP REGISTRATION**

*** NANOSONICS REVENUE UP 3% TO $204m; PROFIT DOWN 14% TO $18m; BUY-BACK**

*** COMPUMEDICS REVENUE UP 18% TO $60m; $1.3m LOSS TO $214k PROFIT**

*** GENETIC SIGS REVENUE DOWN 7% TO $15m; LOSS DOWN 30% TO $14m**

*** PRESCIENT SHARE PLAN FOR $7m**

*** PETER MACCALLUM 'NEW PANCREATIC CANCER DRUG TARGETS, IN VITRO'**

*** VANGUARD TAKES 5% OF CLARITY**

*** PERENNIAL REDUCES TO 6% OF GENETIC SIGNATURES**

*** AUSTRALIAN SUPER REDUCES TO 8% OF ALCIDION**

*** REGAL FUNDS BELOW 5% OF RADIOPHARM**

*** QIMR APPOINTS PROF BRANDON WAINWRIGHT CEO, DIRECTOR**

## MARKET REPORT

The Australian stock market was up 0.68 percent on Tuesday August 25, 2026, with the ASX200 up 61.5 points to 9,164.6 points. Twenty-one of the Biotech Daily Top 40 companies were up, nine fell and 10 traded unchanged.

Paradigm was the best, up 2.5 cents or 12.5 percent to 22.5 cents, with 8.5 million shares traded. EBR and Medical Developments climbed seven percent or more; 4D Medical, Botanix and Curvebeam were up five percent or more; Artrya and Resonance rose more than four percent; Actinogen and Clarity were up more than three percent; Alcidion, Clinuvel and CSL rose more than two percent; Cochlear, Cyclopharm, Dimerix, Immutep, Polynovo, Racura and Resmed were up one percent or more; with Imricor, Neuren, Saluda and Starpharma up by less than one percent.

Nanosonics led the falls, down 63 cents or 17.1 percent to $3.05, with 6.2 million shares traded. Syntara lost 11.1 percent; Imugene was down 7.6 percent; Prescient shed 6.9 percent; Optiscan fell 5.7 percent; Amplia lost 3.3 percent; Orthocell shed 2.5 percent; Aroa and Pro Medicus were down more than one percent; with Avita down by 0.4 percent.

## NEUREN PHARMACEUTICALS

Neuren says partner Acadia Pharmaceuticals has European Union approval for Daybu, or trofinetide, for Rett syndrome, triggering milestones up-to $US205 million ($A287 million).
Neuren said the San Diego, California-based Acadia had approval to market Daybu for the neuro-behavioral symptoms of Rett syndrome in adults and paediatric patients aged five years and older in all 27 European Union member states as well as Iceland, Lichtenstein and Norway.
In 2023, the company said Acadia the US Food and Drug Administration approved Daybue for Rett syndrome for adults and children two years and older (BD: Mar 13, 2023).
Last year, Neuren said Acadia applied to the European Medicines Agency (EMA) for marketing authorization for trofinetide; and later, said the EMA recommended the refusal of its application, with Acadia to appeal (BD: Jan 19, 2025; Feb 3, 2026).
In June, the company said Acadia confirmed the EMA was recommending marketing authorization for trofinetide, known as 'Daybu', for Rett syndrome (BD: Jun 29, 2026).
Today, Neuren said Daybu was "the first and only treatment approved for Rett syndrome in the European Union", with Acadia expected commercial launch in Germany around October 2026.
The company said under its Acadia agreement in Europe it was entitled to receive $US35 million ($A49 million) following first commercial sale, potential sales milestone payments of up to $US170 million ($A238 million) on yearly sales thresholds, and tiered mid-teen-to-low 20 percent royalties on sales.
Neuren managing-director Jon Pilcher said the company was "delighted for the Rett syndrome community in Europe, who, until now, have had no approved treatment for this devastating condition".
"The European Commission's approval of Daybu is particularly rewarding for Neuren given our long-standing commitment to developing therapies for serious neurological disorders with profound unmet need," Mr Pilcher said.
"We look forward to seeing our partner Acadia make Daybu available for Rett patients and families in Europe," Mr Pilcher said.
Neuren was up eight cents or 0.4 percent to $22.53 with 854,480 shares traded.

## CONTROL BIONICS

Control Bionics says it has UK Medicines and Healthcare Products Regulatory Agency registration to commercialize its Neurostrip wearable electro-myography device.
Control Bionics said the registration confirmed its status as a registered medical device manufacturer and allowed it to pursue commercial supply and revenue generation of Neurostrip in England, Scotland and Wales.
Earlier this year, the company said the US Food and Drug Administration had registered and listed Neurostrip as a medical device (BD: Aug 4, 2026).
Today, Control Bionics said the UK offered "a well-established and well-funded rehabilitation and research sector, alongside elite sports markets, all of which represent potential applications for Neurostrip".
The company said three Neurostrip pilot programs were already underway, with "several additional customer trials due to start in September 2026".
Control Bionics managing-director Jeremy Steele said UK registration was "another milestone in our ongoing global commercial expansion".
"Combined with our FDA registration, we are building the foundations to scale Neurostrip across major international markets," Mr Steele said.
Control Bionics was up 0.2 cents or 3.5 percent to 5.9 cents.

## NANOSONICS

Nanosonics says revenue for the year to June 30, 2026 was up 2.65 percent to $203,893,000, with net profit after tax down 13.7 percent to $17,835,000.
Nanosonics said revenue primarily was from its Trophon ultrasound probe cleaning system, as well as its Coris flexible endoscopy cleaning system, with the increase "underpinned by continued growth in total device sales, record upgrade momentum in North America, and ongoing demand for consumables and services".
The company said recurring revenue from consumables and services was up two percent to $149.2 million, with device sales and upgrades up four percent to $54.7 million.
Nanosonics said revenue from North America was up three percent to $186.4 million, in Europe, the UK and the Middle East revenue rose one percent to $12.3 million with the Asia Pacific region revenue fell 14 percent to $5.1 million.
The company said gross margin was in line with expectations at 76.9 percent compared to 78.2 percent in the year to June 30, 2025, with year-on-year moderation reflecting product mix and currency movements.
Nanosonics managing-director Michael Kavanagh said the company was "entering a defining period of growth … [and] 2025-'26 demonstrated the strength of the business we have built, a proven Trophon franchise, disciplined financial execution and in 2026-'27 we will progress the Coris system from [controlled market release] to commercialization".
The company said it recovered $2.5 million in US tariffs paid under the International Emergency Economic Powers Act to February 2026 and that operating expenses were $141.4 million, an increase of two percent "reflecting disciplined cost control while continuing to invest in innovation, operational capability and preparations".
Nanosonics said diluted earnings per share fell 13.75 percent to 5.77 cents, net tangible asset backing per share was up 4.8 percent to 66.01 cents.
The company said that it had cash and cash equivalents of $155,222,000 at June 30, 2026, compared to $161,638,000 at June 30, 2025.
Nanosonics said it would buy-back up-to $40 million in shares on-market for the year to June 30, 2027, following a $20 million buy-back completed in 2025-'26.
Nanosonics fell 63 cents or 17.1 percent to $3.05 with 6.2 million shares traded.

## COMPUMEDICS

Compumedics says revenue for the year to June 30, 2026 was up 18.25 percent to a record $60,254,000, with last year's $1,268,000 net loss turned to a $214,000 profit.
Compumedics said sales of its sleep diagnostics and neurology business including Somfit and Nexus360 fell 6.6 percent to $49.5 million, with magneto-encephalogram (MEG) for brain mapping revenue of $9.7 million and blood flow diagnostics down 4.25 percent to $4.5 million, compared to the previous corresponding period.
The company said that it had implemented a $2 million cost savings program, which included expenditure management, organizational efficiencies and a reset of its US commercial structure.
Compumedics said it continued "to target further double-digit revenue growth in 2026-'27, supported by order book conversion, ongoing MEG activity, continued growth in recurring revenues and progression of Somfit D toward commercial release in the US".
The company said last year's 0.7 cents diluted loss per share was turned a 0.1 cents diluted earnings per share, with net tangible asset backing per share down 22.2 percent to 2.1 cents, with cash and cash equivalents of $6,146,000 at June 30, 2026 compared to $2,690,000 at June 30, 2025.
Compumedics was unchanged at 26.5 cents.

## GENETIC SIGNATURES

Genetic Signatures says revenue for the year to June 30, 2026 fell 6.7 percent to $14,840,000, with net loss after tax down 30.3 percent to $14,006,000.
Genetic Signatures said sales revenue from its Easyscreen kits for respiratory pathogens and various infectious diseases fell due to “a competitive and price sensitive trading environment together with a delayed and muted respiratory testing season in Australia”.
The company said its reduced loss included a $2.1 million impairment expense recognized principally against property, plant and equipment no longer in use.
Genetic Signatures said it entered the year to June 30, 2027 “with new long-term customer contracts, a leaner cost base delivering estimated annualized savings of up-to $5 million, and a clear strategic direction to optimize resources and scale the business”.
The company said diluted loss per share fell 30.4 percent to 6.17 cents, with net tangible asset backing per share down 29.0 percent to 15.7 cents and cash and equivalents of $9,066,000 at June 30, 2026 compared to $7,473,000 in the prior year.
Genetic Signatures was up 0.7 cents or 9.6 percent to 8.0 cents with 1.5 million shares traded.

## PRESCIENT THERAPEUTICS

Prescient says it hopes to raise $7 million at 6.5 cents a share in a share purchase plan to fund the development of its cancer treatment PTX-100.
Prescient said the issue price was an 18.8 percent discount to the 10-day volume weighted average price and a 9.7 percent discount to the last price.
The company said the funds would be used for, business development and portfolio management activities, including the evaluation of complementary pipeline opportunities.
Prescient said the plan, would open on August 26 and close on September 8, 2026.
Prescient fell half a cent or 6.9 percent to 6.7 cents with 4.3 million shares traded.

## PETER MACCALLUM CANCER CENTRE

The Peter MacCallum Cancer Centre says it has found “potential drug targets for pancreatic cancer … in proteins cancer cells rely on to grow and survive” in-vitro.
The Peter MacCallum Centre said a study of the transcriptional cyclin-dependent kinases, or tCDKs, protein family tested a range of drugs designed to block different tCDKs in pancreatic ductal adeno-carcinoma cells, the most common form of pancreatic cancer.
The Centre said that targeting several of the proteins stopped the cancer cells from growing and multiplying, with pancreatic cancer cells “highly sensitive to drugs targeting four proteins known as CDK9, CDK11, CDK12 and CDK13”.
Peter MacCallum said the study, titled ‘Sensitivity of pancreatic adenocarcinoma cells to blockade of post-initiation CDK-dependent Pol II transcription cycle checkpoints’ was published in Molecular Cancer Therapeutics and available at: https://bit.ly/3UR9d2C.
Co-senior study author Dr Jennifer Devlin said cancer cells depended “on certain genes being constantly active to support their growth and survival”.
“We wanted to understand whether disrupting the machinery that allows pancreatic cancer cells to keep these genes switched on could expose a weakness that could potentially be targeted with new treatments,” Dr Devlin said.
“These proteins help control crucial stages of the process that allows genetic instructions to be copied into RNA, which cells then use to carry out their functions,” Dr Devlin said.
“When we blocked these stages, we saw a strong impact on the ability of pancreatic cancer cells to produce new RNA and to continue multiplying,” Dr Devlin said.

## CLARITY PHARMACEUTICALS

The Philadelphia, Pennsylvania-based Vanguard Group says it has become a substantial shareholder in Clarity with 18,932,774 shares, or 5.075 percent of the company.
Vanguard said between May 15 and August 19, 2026 it bought shares from $2.10 to $2.63 a share and sold shares at $1.82 to $2.70 a share.
Clarity was up nine cents or 3.8 percent to $2.48 with 1.5 million shares traded.

## GENETIC SIGNATURES

Perennial Value Management says it has reduced its substantial shareholding in Genetic Signatures from 33,647,760 shares (14.81%) to 14,339,393 shares (6.31%).
Sydney's Perennial said it bought and sold shares between June 18 and August 24, 2026 with the single largest sale 8,745,224 shares for $698,079, or 8.0 cents a share.

## ALCIDION GROUP

Melbourne's Australian Super says it has reduced its substantial shareholding in Alcidion from 126,691,397 shares (9.43%) or 107,639,465 shares (8.01%).
Australian Super said it sold shares between January 16 and August 20, 2026, with the single largest sale 6,882,489 shares on August 20 for $635,873, or 9.2 cents a share.
Alcidion was up 0.2 cents or 2.1 percent to 9.6 cents.

## RADIOPHARM THERANOSTICS

Sydney's Regal Partners Funds Management says it has ceased its substantial shareholding in Radiopharm.
Regal Funds said that on August 14 and 20, 2026 it sold 101,562,882 shares for $1,054,792, or 1.0 cent a share and 162 American depository shares, representing 300 ordinary shares each, for $397, or $2.45 a share.
Last week, Regal said it held 266,738,212 shares; and according to its last filing, Radiopharm had 4,337,549,491 shares on issue, meaning that Regal retained about 3.8 percent of the company (BD: Aug 18, 2026).
Radiopharm fell 0.05 cents or 4.55 percent to 1.05 cents.

## QUEENSLAND INSTITUTE OF MEDICAL RESEARCH (QIMR) BERGHOFER

QIMR Berghofer says it has appointed Prof Brandon Wainwright as its director and chief executive officer, effective from September 7, 2026.
QIMR said that Prof Wainwright was "an internationally recognized geneticist and highly experienced research leader whose career has spanned biomedical discovery, translation, and leadership across the Australian medical research sector".
The Institute said Prof Wainwright was currently a professor at the University of Queensland and co-director of the Children's Brain Cancer Centre.
QIMR Berghofer said Prof Wainwright completed his undergraduate and graduate studies at the University of Adelaide.